A drug that blocks cannabinoid receptors outside the brain improved memory, synaptic function and gut abnormalities in mouse models of fragile X syndrome. The findings strengthen evidence that the microbiota–gut–brain axis may contribute to cognitive symptoms and could offer a new route for developing treatments with fewer central nervous system effects.
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.